In a very recent network meta-analysis of cardiovascular events in ICIs-treated lung cancer patients authors highlight on the higher incidence of myocarditis, pericarditis and vasculitis in CTLA-4 blocking agents associated to chemotherapy or PDL-1 therapy regimen compared to monotherapy, indicating mechanisms of cardiotoxic synergism in combinatorial ICIs therapy (65). This evidence concerns the gene CTLA4 and myocarditis.